ABSTRACT

An accurate, precise and reproducible HPLC method was developed for quantitative estimation of Omeprazole (OPZ) and Ondansetron (ODN) simultaneously in tablet dosage forms. Omeprazole is a proton pump inhibitor and in the treatment of gastro-oesophageal reflux disease (GERD), peptic ulcer and Zollinger-Ellison syndrome. Ondansetron is used as selective 5-HT3 receptor antagonist and used in the management of nausea and vomiting induced by cytotoxic chemotherapy and radio therapy and also post operative nausea and vomiting. Agilent (S. K.) gradient system UV detector and C18 column with 100 mm x 4.6 mm i.d. and 5?m particle size. Methanol: water (70:30) 0.1 % OPA was used as the mobile phase for the method. The detection wavelength was 259 nm and flow rate was 0.8 ml/min and temperature 26° C ambien. In the developed method, the retention time of omeprazole and ondansetron were found to be 4.01 min and 6.95 min. The developed method was validated according to the ICH guidelines. The linearity, precision, range, robustness was within the limits as specified by the ICH guidelines. Hence the method was found to be simple, accurate, precise, economic and reproducible. So the proposed methods can be used for the routine quality control analysis of omeprazole and ondansetron in bulk drug as well as in formulations. Keywords: Omeprazole and Ondansetron, method development, validation, simultaneous estimation, HPLC
Publication date: 01/04/2022

https://ijbpas.com/pdf/2022/April/MS_IJBPAS_2022_6034.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.4.6034